Innovative Product Portfolio Biosensors International offers a robust line of advanced interventional cardiology devices, including the BioMatrix™ DES family and BioFreedom™ systems, which have achieved international regulatory approvals such as US FDA and Japanese PMDA. These innovative solutions present opportunities for hospitals and clinics seeking proven, cutting-edge cardiovascular treatments.

Strategic Growth Through Acquisition The recent acquisition of New Valve Technology enhances Biosensors’ capabilities in structural heart disease interventions, particularly with the Allegra™ TAVI system. This expansion into structural heart markets provides potential sales avenues with institutions specializing in minimally invasive valve procedures.

Expanding Global Presence With approvals in key markets like Japan and the US and ongoing clinical trials, Biosensors is positioning itself as a global leader. Sales teams can focus on regions showing regulatory clearance and clinical validation to accelerate device adoption and market penetration.

Strong Clinical Validation Clinical trial results and recent study launches, such as RISE SC and BIO-RISE China, demonstrate the efficacy and safety of Biosensors’ products. Leveraging this data can support educational and promotional efforts aimed at leading cardiology centers and specialists.

Growing Revenue with Tech Focus With an annual revenue between $100M and $250M and continuous new product launches, Biosensors is experiencing growth driven by innovative device development. Business development efforts can target high-volume hospitals and health systems eager to adopt proven, high-tech cardiovascular solutions.